BNET Industries

QIAGEN N.V.

QGEN is in the Pharma Industry

Market Cap:$4.3B

Last Fiscal Year Sales:$892.9M

Public
NL

Dow Jones Description

QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis. We have developed more than 500 consumable products and automated solutions. We sell these products to academic research markets, to leading pharmaceutical and biotechnology companies, to molecular diagnostics laboratories as well as to customers in applied testing markets such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN employs more than 2,600 people in over 30 locations worldwide.

Number of Employees 3,041

Contact Information

Spoorstraat 50

Venlo 5911 KJ

www.qiagen.com

(31) 77 320 8400

Peer Companies

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Company News

Recent Events

Qiagen NV QGEN Posts Q3 EPS of $0.26, Tops by 3c; Raises FY09 EPS

11/10/09 - Financial Announcement - View Story
BioWatch: Deal fits Sigma-Tau's focus on rare diseases

11/14/09 - Merger / Acquisition - View Story
QIAGEN signs commercialization agreemenet with Veterinary Laboratories Agency for three PCR-based tests in horses

11/06/09 - Joint Venture / Alliance - View Story
Qiagen N.V. DE - QIAGEN to Acquire SABiosciences

11/10/09 - Merger / Acquisition - View Story
Qiagen CEO says eyes more diagnostics takeovers

10/20/09 - Merger / Acquisition - View Story
QIAGEN acquires DxSf??? in an all stock transaction of USD95m

9/23/09 - Merger / Acquisition - View Story
QIAGEN acquires DxSAin an all stock transaction of USD95m

9/23/09 - Merger / Acquisition - View Story
Qiagen raises capital, buys DxS of Britain

9/23/09 - New Investment - View Story
Qiagen's $130M Purchase of DxS a 13X Profit for Investors

9/30/09 - Merger / Acquisition - View Story
Qiagen Acquires Addl. PCR Licenses From Roche And Idaho Technology; Terms Not Disclosed - Quick...

9/17/09 - Product Announcement - View Story
QIAGEN launches new Pandemic Influenza A/H1N1 detection kit

9/10/09 - Product Announcement - View Story
Biomatrica Unveils Qiagen's New QIAsafe DNA Blood Products - Quick Facts

9/10/09 - Product Announcement - View Story
More

7/05/09 - Joint Venture / Alliance - View Story
Plexus Awarded Development Contract With QIAGEN

5/28/09 - Joint Venture / Alliance - View Story

News & Analysis

qiagen n.v. - All News and Analysis

QIAGEN Introduces Novel Tools for miRNA Analysis

- 2008-06-25

Company expands portfolio by adding four new sample and assay solutions for this rapidly emerging area of molecular research Venlo, The Netherlands - June 25, 2008 - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the launch of four...

Tags: Company, QIAGEN N.V.
Sports Doping Researchers to Tackle Mount Everest

- 2008-05-26

In the run-up to the Olympics scientists use live mice for the first time on the "roof of the world" to develop new tests for gene doping Hilden, Germany / Everest Base Camp, Nepal - May 26, 2008 - In the run-up to the Summer...

Tags: QIAGEN N.V.
QIAGEN and GENEART Partner to Commercialize Synthetic Mammalian Genes

- 2008-05-14

- Complete set of mammalian genes is optimized & produced by GENEART and sold via QIAGEN's GeneGlobe web portal - Joint development and collaboration enables enhanced production of e.g. every human protein, spurring advances in drug development - Strategic partnership with QIAGEN to market standardized ...

Tags: GENEART, QIAGEN N.V.
QIAGEN and GENEART Partner to Commercialize Synthetic Human Genes

- 2008-05-14

Joint development and collaboration enables enhanced production of every human protein, spurring advances in drug development Venlo, The Netherlands --- May 14, 2008 - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and GENEART (Frankfurt, Entry Standard, G6A) announced their collaboration to develop, produce and commercialize a new...

Tags: GENEART, QIAGEN N.V.
Rickettsia felis in fleas, France

- 2008-04-01

To the Editor: Rickettsia felis belongs to the spotted fever group of rickettsia. The pathogenic role of this intracellular Proteobacteria in humans has been reported in patients from the United States Texas (1), Mexico (2), Germany (3), Brazil, and France (4). R. felis is widely distributed, is associated with blood-sucking...

Tags: QIAGEN N.V., Roche Holding AG

U.S. Scientist Receives Otto Warburg Medal Sponsored by QIAGEN

- 2008-03-27

Embargoed until 4 p.m. CET/ 11 a.m. EST today. Susan Lindquist Recognized for Contributing to Molecular Understanding of Parkinson's Disease Mosbach, Germany, Mar. 27, 2008 - American scientist Susan Lindquist, Ph.D., was awarded today the Otto Warburg Medal in Mosbach, Germany. The medal is considered the most prestigious...

Tags: QIAGEN N.V.
Hemagglutinating encephalomyelitis coronavirus infection in pigs, Argentina

- 2008-03-01

We describe an outbreak of vomiting, wasting, and encephalomyelitis syndrome in piglets in Argentina, caused by porcine hemagglutinating encephalomyelitis coronavirus (PHE-CoV) infection. Diagnosis was made by epidemiologic factors, pathologic features, immunohistochemistry, reverse transcription-PCR, and genomic sequencing. This study documents PHE-CoV infection in South America. ********** Porcine hemagglutinating encephalomyelitis...

Tags: QIAGEN N.V.
QIAGEN opens New Service Solutions Center in Asia

- 2008-02-22

QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today opened a new Service Solutions Center in Singapore for the Asia-Pacific region. The facility completes the Company's global Service Solution Network by adding a center in the Asia-Pacific region to its existing centers in...

Tags: QIAGEN N.V.
QIAsymphony SP Wins "Best New Product" Award

- 2008-01-30

ALA's prestigious award recognizes QIAGEN's novel sample and assay processing platform for its technical originality and innovative features VENLO, The Netherlands, January 30, 2008 - QIAGEN N.V. today announced that its new modular platform ...

Tags: QIAGEN N.V.
QIAGEN Introduces Novel Modular Processing Platform

- 2008-01-28

QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the launch of QIAsymphony® SP, the first system of the novel modular platform QIAsymphony which offers laboratories a new level of flexibility, convenience and safety in automated processing of...

Tags: QIAGEN N.V.